Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Open-label Study of Intravenous Iron Isomaltoside 1000 (Monofer®) as Mono Therapy (Without Erythropoiesis Stimulating Agents) in Comparison With Oral Iron Sulfate in Subjects With Non-myeloid Malignancies Associated With Chemotherapy Induced Anaemia (CIA)

NCT01145638 is registered in ClinicalTrials.gov with Pharmacosmos A/S as lead sponsor.

NCT NCT01145638
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01145638 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Open-label Study of Intravenous Iron Isomaltoside 1000 (Monofer®) as Mono Therapy (Without Erythropoiesis Stimulating Agents) in Comparison With Oral Iron Sulfate in Subjects With Non-myeloid Malignancies Associated With Chemotherapy Induced Anaemia (CIA)
Lead sponsor
Pharmacosmos A/S
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2010
Completion date
May 31, 2014
Enrollment
350 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy induced anaemia, non-myeloid malignancies